New plant on its Mourenx, France site to produce a large volume commercial API

15-10-2012

Novasep announced an investment of EUR 30 million to build in Europe what will be the world's largest chromatography plant used for the production of a large volume commercial API (active pharmaceutical ingredient).The plant will be built on Novasep's existing Mourenx site in France and will ...

more

23-07-2012

Novasep announces a EUR three million investment to expand its Highly Potent API (HPAPI) manufacturing capabilities at its facility in Le Mans, France. The expansion has been designed to allow Novasep to serve the increased demand for manufacturing of novel anti-cancer therapies. Demand in ...

more

Appointment of Jean-Claude Romain as corporate quality director and Alain Lamproye as director of Novasep Bioproduction sites in Belgium

25-04-2012

Novasep announced two new managerial appointments. Jean-Claude Romain becomes the group's corporate quality director and a member of Novasep's executive committee, while Alain Lamproye joins Novasep Process, the company's biomolecules division, as director of Novasep Belgium and becomes a ...

more

New site increases Novasep’s process development and engineering capabilities to supply turnkey purification processes in East Asia

28-03-2012

Novasep announced the opening of a new 2,000 m2 facility in Shanghai Pudong district, China. The site will boost Novasep's process development and engineering capabilities to cater for ever-increasing Chinese and East Asian demand. These facilities will also add to Novasep’s existing 12 ...

more

Novasep’s pharmaceutical production excellence in Europe and the Bahamas recognized by two successful FDA inspections in 2011

29-07-2011

Novasep announced today that it has completed two successful US Food and Drug Administration (FDA) inspections for Novasep Synthesis in 2011. All five Novasep Synthesis sites passed FDA inspections in the last three years, the most recent ones at its Freeport (the Bahamas) facility in March ...

more

Companies will develop solutions to change manufacturing paradigm for new and generic anti-cancer compounds

15-02-2011

Novasep, a leading supplier of manufacturing solutions to the life science industries, and instrAction, a manufacturer of innovative chromatographic stationary phases for API purification processes, announced they have expanded their worldwide strategic alliance to include the purification of ...

more

11-11-2010

Nutritis and Novasep Process, a division of Novasep, announced that, thanks to Novasep Process, Nutritis will scale up its production process for fructose from apple juice. Nutritis brought in Novasep to use the latter’s purification expertise to scale up its innovative process. Nutritis and ...

more

Bernard Dubois, Former Aventis Senior VP of Global Industrial Operations Brings a Wealth of Experience to Novasep's Top Management Team

06-09-2010

Novasep announced the appointment of Bernard Dubois as Chairman of its supervisory board. Bernard Dubois replaces Pietro Stefanutti, who decided to allocate most of his time to personal activities. As a graduate of the renowned Ecole Polytechnique (France) with an MBA from Cornell University ...

more

27-07-2010

Cerenis Therapeutics SA and Groupe Novasep announced that they have received French Government funding through OSEO to finance the development of CER-001, a Cerenis HDL mimetic. CER-001 represents a promising new approach in the fight against atherosclerotic cardiovascular disease and has ...

more

21-07-2010

Novasep and instrAction announced that they have entered a strategic alliance. The alliance will offer customers in the life science industry a combination of instrAction’s proprietary API-selective stationary phases (Instruction® Receptor Phase) and Novasep purification capabilities and high ...

more